Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mereo BioPharma Group (MREO) FCF Margin: 2023-2025

Historic FCF Margin for Mereo BioPharma Group (MREO) over the last 3 years, with Sep 2025 value amounting to -2,687.13%.

  • Mereo BioPharma Group's FCF Margin fell 481716.00% to -2,687.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 10,660.91%, marking a year-over-year increase of 51404425.00%. This contributed to the annual value of 2,396.64% for FY2024, which is 260796.00% up from last year.
  • According to the latest figures from Q3 2025, Mereo BioPharma Group's FCF Margin is -2,687.13%, which was down 108.43% from 31,879.17% recorded in Q2 2025.
  • In the past 5 years, Mereo BioPharma Group's FCF Margin ranged from a high of 31,879.17% in Q2 2025 and a low of -2,687.13% during Q3 2025.
  • Moreover, its 3-year median value for FCF Margin was 2,130.03% (2024), whereas its average is 3,949.92%.
  • Data for Mereo BioPharma Group's FCF Margin shows a peak YoY increase of 2,949,125bps (in 2025) and a maximum YoY decrease of 481,716bps (in 2025) over the last 5 years.
  • Mereo BioPharma Group's FCF Margin (Quarterly) stood at -678.90% in 2023, then soared by 319,090bps to 2,512.00% in 2024, then plummeted by 481,716bps to -2,687.13% in 2025.
  • Its FCF Margin was -2,687.13% in Q3 2025, compared to 31,879.17% in Q2 2025 and 4,638.33% in Q1 2025.